Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018973 | 1.00 | LMNA (0.48) | LMNARAB9AGAAALDH1A1KMT2A | |
| SCHEMBL3007286 | 0.81 | KDR (0.60) | LMNARAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL3020104 | 0.81 | KDR (0.60) | LMNARAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL4865097 | 0.76 | POLB (0.40) | RAB9AGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL3010875 | 0.76 | KMT2A (0.54) | LMNARAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL3010871 | 0.76 | KMT2A (0.54) | LMNARAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL4751206 | 0.74 | RAB9A (0.60) | LMNARAB9AGAAALDH1A1KMT2A | |
| SCHEMBL4751207 | 0.74 | RAB9A (0.60) | LMNARAB9AGAAALDH1A1KMT2A | |
| SCHEMBL4866567 | 0.73 | ALDH1A1 (0.46) | LMNARAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL29021933 | 0.73 | NPC1 (0.40) | GAAALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162991-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITY OF OTTAWA (CA) | 2015-10-20 | — | — | US | disclosed |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2014-01-23 | — | — | US | disclosed |
| US-8614233-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITE DE MONTREAL (CA) | 2013-12-24 | — | — | US | disclosed |
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TGM1 | LMNA 2273/4885RAB9A 2132/4885GAA 12/4885 |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TFPI | LMNA 1764/4885RAB9A 2229/4885GAA 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.